• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

富含或富含浸润淋巴细胞的 DNA 错配修复功能正常和有缺陷的结肠肿瘤中的肿瘤内 T 细胞受体库。

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes.

机构信息

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

出版信息

Oncoimmunology. 2022 Apr 14;11(1):2054757. doi: 10.1080/2162402X.2022.2054757. eCollection 2022.

DOI:10.1080/2162402X.2022.2054757
PMID:35481287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9037499/
Abstract

Colon tumors with deficient DNA mismatch repair (dMMR) are generally infiltrated by T cells more densely than tumors with proficient mismatch repair (pMMR). However, high numbers of tumor-infiltrating lymphocytes (TILs) are found in select pMMR tumors, and low numbers of TILs are seen in select dMMR tumors. In this study, we compared T-cell repertoires in 20 pMMR and 27 dMMR colon tumors with high and low TIL counts. We found that T cells in dMMR tumors are more clonal and their repertoire is less rich compared with T cells in pMMR tumors. In the dMMR group, T cells in TIL-high tumors were more clonal and their repertoire was less rich compared with T cells in TIL-low tumors, but in the pMMR group, T-cell diversity in TIL-high tumors was comparable to T-cell diversity in TIL-low tumors. These findings suggest that T cells clonally expand in dMMR tumors, possibly in response to MMR deficiency-induced tumor neoantigens.

摘要

与错配修复功能完整(pMMR)的肿瘤相比,错配修复功能缺陷(dMMR)的结肠肿瘤通常有更密集的 T 细胞浸润。然而,在一些 pMMR 肿瘤中也发现了大量的肿瘤浸润淋巴细胞(TIL),而在一些 dMMR 肿瘤中则发现了少量的 TIL。在这项研究中,我们比较了 20 例高 TIL 计数和 27 例低 TIL 计数的 pMMR 和 dMMR 结肠肿瘤中的 T 细胞受体库。我们发现,与 pMMR 肿瘤中的 T 细胞相比,dMMR 肿瘤中的 T 细胞更具克隆性,其受体库也不那么丰富。在 dMMR 组中,TIL 高肿瘤中的 T 细胞比 TIL 低肿瘤中的 T 细胞更具克隆性,其受体库也不那么丰富,但在 pMMR 组中,TIL 高肿瘤中的 T 细胞多样性与 TIL 低肿瘤中的 T 细胞多样性相当。这些发现表明,T 细胞在 dMMR 肿瘤中克隆性扩增,可能是对 MMR 缺陷诱导的肿瘤新抗原的反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee6d/9037499/f9e46267b1fb/KONI_A_2054757_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee6d/9037499/97436806fbd7/KONI_A_2054757_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee6d/9037499/2c9a56f6c547/KONI_A_2054757_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee6d/9037499/f9e46267b1fb/KONI_A_2054757_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee6d/9037499/97436806fbd7/KONI_A_2054757_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee6d/9037499/2c9a56f6c547/KONI_A_2054757_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee6d/9037499/f9e46267b1fb/KONI_A_2054757_F0003_OC.jpg

相似文献

1
Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes.富含或富含浸润淋巴细胞的 DNA 错配修复功能正常和有缺陷的结肠肿瘤中的肿瘤内 T 细胞受体库。
Oncoimmunology. 2022 Apr 14;11(1):2054757. doi: 10.1080/2162402X.2022.2054757. eCollection 2022.
2
Certain pMMR colorectal cancer patients should undergo additional MSI-PCR testing to reduce the risk of misdiagnosing MSI-H and Lynch syndrome.某些错配修复功能完整(pMMR)的结直肠癌患者应接受额外的微卫星不稳定性聚合酶链反应(MSI-PCR)检测,以降低误诊为微卫星高度不稳定(MSI-H)和林奇综合征的风险。
BMC Cancer. 2025 Jul 1;25(1):1103. doi: 10.1186/s12885-025-14484-3.
3
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.DNA 错配修复缺陷和肿瘤内异质性缺乏对弥漫性大 B 细胞淋巴瘤的免疫反应有不同影响。
Oncoimmunology. 2024 Aug 5;13(1):2384667. doi: 10.1080/2162402X.2024.2384667. eCollection 2024.
4
Intertumoral Heterogeneity of CD3 and CD8 T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis.错配修复缺陷型结直肠肿瘤微环境中 CD3 和 CD8 T 细胞密度的肿瘤间异质性:对预后的影响。
Clin Cancer Res. 2019 Jan 1;25(1):125-133. doi: 10.1158/1078-0432.CCR-18-1984. Epub 2018 Oct 9.
5
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.肿瘤淋巴细胞反应和 DNA 错配修复缺陷可识别与患者结局相关的 II/III 期结直肠癌亚型。
Gut. 2019 Mar;68(3):465-474. doi: 10.1136/gutjnl-2017-315664. Epub 2018 Jan 30.
6
Second malignancies in patients with deficient mismatch repair system/microsatellite instability-high colorectal cancer.错配修复缺陷系统/微卫星高度不稳定型结直肠癌患者的第二原发性恶性肿瘤
Therap Adv Gastroenterol. 2025 Jun 21;18:17562848251347375. doi: 10.1177/17562848251347375. eCollection 2025.
7
Characteristics of Mismatch Repair-Deficient Colon Cancer in Relation to Mismatch Repair Protein Loss, Hypermethylation Silencing, and Constitutional and Biallelic Somatic Mismatch Repair Gene Pathogenic Variants.错配修复缺陷型结直肠癌的特征与错配修复蛋白缺失、高甲基化沉默以及胚系和双等位基因体细胞错配修复基因致病性变异有关。
Dis Colon Rectum. 2023 Apr 1;66(4):549-558. doi: 10.1097/DCR.0000000000002452. Epub 2022 Jun 20.
8
Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers.整合空间图谱与癌症基因组学以识别免疫浸润的错配修复 proficient 结直肠癌。 注:原文中“proficient”可能有误,根据语境推测可能是“deficient”(缺陷的),若为“deficient”,则译文为:整合空间图谱与癌症基因组学以识别免疫浸润的错配修复缺陷型结直肠癌。
bioRxiv. 2024 Sep 26:2024.09.24.614701. doi: 10.1101/2024.09.24.614701.
9
Immunohistochemical and molecular evolutionary features of jejunoileal adenocarcinoma unveiled through comparative analysis with colorectal adenocarcinoma.通过与结直肠癌的比较分析揭示空回肠腺癌的免疫组织化学和分子进化特征。
Neoplasia. 2025 Aug;66:101180. doi: 10.1016/j.neo.2025.101180. Epub 2025 May 21.
10
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.BRAF V600E 突变且错配修复缺陷或微卫星不稳定高转移性结直肠癌患者在免疫检查点抑制剂后使用 BRAF+EGFR+/-MEK 抑制剂。
Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290. Epub 2024 Aug 22.

引用本文的文献

1
A laminin α4-CD8 T cell axis shapes the prognostic impact of macrophages and regulatory T cells in early-stage colorectal cancer.层粘连蛋白α4-CD8 T细胞轴塑造了巨噬细胞和调节性T细胞在早期结直肠癌中的预后影响。
Oncoimmunology. 2025 Dec;14(1):2546181. doi: 10.1080/2162402X.2025.2546181. Epub 2025 Aug 12.
2
Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer.肿瘤侵袭防御指数——预测Ⅱ-Ⅲ期结直肠癌复发和生存的新型指标。
J Transl Med. 2025 Jan 22;23(1):107. doi: 10.1186/s12967-025-06141-x.
3
Tumor Microenvironment Biomarkers Correlated with Proliferative Activity and Immune Response in Extragastrointestinal Stromal Tumors: Exploring Variations in Different Age Groups.

本文引用的文献

1
Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant Colon Cancer.肿瘤浸润淋巴细胞、肿瘤突变负担以及微卫星不稳定、微卫星稳定或突变型结直肠癌中的遗传改变。
JCO Precis Oncol. 2021 May 12;5. doi: 10.1200/PO.20.00456. eCollection 2021.
2
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.帕博利珠单抗治疗微卫星高度不稳定型晚期结直肠癌。
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
3
Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer.
与胃肠道外间质瘤增殖活性和免疫反应相关的肿瘤微环境生物标志物:探索不同年龄组的差异
Maedica (Bucur). 2024 Jun;19(2):233-238. doi: 10.26574/maedica.2024.19.2.233.
4
Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.错配修复 proficient 肿瘤足迹在免疫荒漠的沙中:机械约束和精确平台。
Front Immunol. 2024 Jul 19;15:1414376. doi: 10.3389/fimmu.2024.1414376. eCollection 2024.
5
Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer.探讨缺陷错配修复(dMMR)直肠癌的免疫检查点抑制剂治疗进展。
Curr Oncol. 2023 Mar 26;30(4):3672-3683. doi: 10.3390/curroncol30040279.
6
Neoantigens: promising targets for cancer therapy.肿瘤新抗原:癌症治疗的有前途的靶点。
Signal Transduct Target Ther. 2023 Jan 6;8(1):9. doi: 10.1038/s41392-022-01270-x.
错配修复功能正常的结肠癌中肿瘤浸润淋巴细胞的定量评估
Oncoimmunology. 2020 Nov 11;9(1):1841948. doi: 10.1080/2162402X.2020.1841948.
4
Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.Ⅱ期微卫星稳定结直肠肿瘤中的淋巴细胞浸润:一项回顾性预后生物标志物分析。
PLoS Med. 2020 Sep 24;17(9):e1003292. doi: 10.1371/journal.pmed.1003292. eCollection 2020 Sep.
5
The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution.微卫星不稳定癌症的共享移码突变景观表明肿瘤进化过程中的免疫编辑。
Nat Commun. 2020 Sep 21;11(1):4740. doi: 10.1038/s41467-020-18514-5.
6
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.免疫评分在接受奥沙利铂治疗的 III 期结肠癌患者中的预后和预测价值:法国 IDEA PRODIGE-GERCOR 前瞻性队列研究。
Ann Oncol. 2020 Jul;31(7):921-929. doi: 10.1016/j.annonc.2020.03.310. Epub 2020 Apr 12.
7
The Immunoscore: Colon Cancer and Beyond.免疫评分:结肠癌及其他癌症
Clin Cancer Res. 2020 Jan 15;26(2):332-339. doi: 10.1158/1078-0432.CCR-18-1851. Epub 2019 Aug 14.
8
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.肿瘤突变负荷可预测多种癌症类型免疫治疗后的生存情况。
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
9
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.癌症类型内及跨癌症类型的免疫和基因状态综合分析:突变特征超出肿瘤突变负荷的影响
Oncoimmunology. 2018 Oct 19;7(12):e1526613. doi: 10.1080/2162402X.2018.1526613. eCollection 2018.
10
Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.谱系追踪揭示结直肠癌中 T 细胞的动态关系。
Nature. 2018 Dec;564(7735):268-272. doi: 10.1038/s41586-018-0694-x. Epub 2018 Oct 29.